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Abstract
Objective: Within the past decade, important genetic drivers of pheochromocytoma and paraganglioma (PPGLs) 
development have been identified. The pathophysiological mechanism that translates these alterations into 
functional autonomy and potentially malignant behavior has not been elucidated in detail. Here we used MALDI-
mass spectrometry imaging (MALDI-MSI) of formalin-fixed paraffin-embedded tissue specimens to comprehensively 
characterize the metabolic profiles of PPGLs.
Design and methods: MALDI-MSI was conducted in 344 PPGLs and results correlated with genetic and phenotypic 
information. We experimentally silenced genetic drivers by siRNA in PC12 cells to confirm their metabolic impact  
in vitro.
Results: Tissue abundance of kynurenine pathway metabolites such as xanthurenic acid was significantly lower 
(P = 2.35E−09) in the pseudohypoxia pathway cluster 1 compared to PPGLs of the kinase-driven PPGLs cluster 2. Lower 
abundance of xanthurenic acid was associated with shorter metastasis-free survival (log-rank tests P = 7.96E−06) and 
identified as a risk factor for metastasis independent of the genetic status (hazard ratio, 32.6, P = 0.002). Knockdown of 
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Sdhb and Vhl in an in vitro model demonstrated that inositol metabolism and sialic acids were similarly modulated as in 
tumors of the respective cluster.
Conclusions: The present study has identified distinct tissue metabolomic profiles of PPGLs in relation to tumor 
genotypes. In addition, we revealed significantly altered metabolites in the kynurenine pathway in metastatic PPGLs, 
which can aid in the prediction of its malignant potential. However, further validation studies will be required to 
confirm our findings.
Introduction
Pheochromocytomas and paragangliomas (PPGLs) are 
neuroendocrine tumors that arise from the adrenal medulla 
and from sympathetic paraganglia, respectively. Although 
the majority of PPGLs follow a benign disease course, up 
to 20% of tumors can develop metastatic spread, which 
defines malignant behavior (1). Over the years, targeted 
and untargeted genomic studies have revealed that PPGL 
tumorigenesis is driven mainly by germline or somatic 
mutations in susceptibility genes comprising SDHA, 
SDHB, SDHC, SDHD, SDHAF2 (collectively referred to as 
SDHx), FH, MDH2, SLC25A11 (2), EPAS1, VHL, NF1, HRAS, 
FGFR1, RET, TMEM127, and MAX (3, 4, 5). Based on the 
transcriptomic classification, PPGL tumors can be grouped 
into three clusters (6). Cluster 1 includes tumors driven 
by germline or somatic mutations in SDHx, VHL, EPAS1 
or genes encoding members of the Krebs cycle pathway 
FH and MDH2 (6, 7). In contrast, the cluster 2 subgroup 
comprises familial or sporadic tumors with underlying 
RET, NF1, TMEM127, HRAS, KIF1B, and MAX mutations 
(7). The third cluster is called the Wnt-altered subtype, 
driven by MAML3 fusions and CSDE1 somatic mutations 
(5). There is ample evidence that SDHB/FH mutations are 
associated with a high risk toward metastatic progression 
(8, 9, 10). Clinical parameters, including primary tumor 
size and extra-adrenal location, are further clinical risk 
factors for malignancy (11).
Analysis of plasma and urinary metanephrine, 
normetanephrine and 3-methoxytyramine from PPGL 
patients has demonstrated secretory patterns, which 
are strongly associated with the underlying genotypes 
(12, 13). A recent quantitative metabolomics study of 
plasma samples has further identified distinct alterations 
in metabolic patterns that resolved upon PPGL removal 
(14). Tissue metabolome profiling of fresh frozen PPGLs 
has previously been performed with a particular focus on 
SDH deficiency and provided evidence of higher succinate: 
fumarate ratios of SDHx mutant vs wild type tumors 
indicative of impaired Krebs cycle and respiratory chain 
(15, 16). NMR spectroscopy in a small number of frozen 
tissue homogenates showed that PPGL clusters not only 
differ in their adenine nucleoside phosphate content but 
also in guanosine content (17). A more comprehensive 
picture of tissue metabolic processes, however, is lacking.
Recent advances in MALDI-mass spectrometry imaging 
(MSI) permit the superimposing of metabolic data with the 
spatial information conveyed by conventional histology. 
This technique has recently allowed us to refine the 
functional anatomy of the human adrenal gland (18, 19), 
has provided novel biomarkers and pathways associated 
with malignant behavior in adrenocortical carcinoma 
(20) and has yielded insight into genotype/phenotype 
correlations of aldosterone-producing adenoma (21). Here, 
we report the first comprehensive MALDI-MSI study of a 
large set of PPGLs with rich genetic and clinical information 
in order to gain further insights into PPGL pathogenesis 
and clinical outcome of patients with this condition.
Subjects and methods
Patient cohort
A total of 344 PPGL tumors were retrieved from 8 specialized 
European centers: (i) Klinikum der Universität München, 
Munich, Germany (74 samples), (ii) UniversitätsSpital 
Zürich, Zurich, Switzerland (69 samples), (iii) University of 
Würzburg, Würzburg, Germany (60 samples), (iv) Hôpital 
Européen Georges Pompidou, Paris, France (54 samples), 
(v) Technische Universität Dresden, Dresden, Germany 
(29 samples), (vi) University of Florence, Florence, Italy (28 
samples), (vii) CNIO, Spain and Centro de Investigación 
Biomédica en Red de Enfermedades Raras (CIBERER), 
Madrid, Spain (23 samples), and (viii) University 
Medical Center Rotterdam, Rotterdam, The Netherlands 
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(7 samples). Diagnostic workup was done following 
established pathways based on clinical, biochemical, and 
morphological data according to the Endocrine Society 
Clinical Practice Guidelines (1). Twenty-one samples (21 out 
of 344; 6.1%) from 19 patients were considered malignant: 
In accordance with the Endocrine Society Clinical 
Practice Guidelines (1), metastatic disease was defined as 
the presence of metastases in non-chromaffin tissue. The 
detection of metastasis was based on the combination 
of imaging studies including functional imaging in 15 
patients (6 patients with MIBG, 6 patients with FDG-PET, 3 
patients with F-DOPA-PET, 2 patients with Ga-DOTATATE 
PET/CT and 1 with somatostatin receptor scintigraphy) 
and histopathology after surgical removal in 8 patients. As 
a total, 17 primary tumors and 4 metastases to other organs 
were found. All patients had provided written informed 
consent and the study was approved by ethical committees 
at all participating institutions. Genetic examination 
and measurement of urine samples are described in the 
supplementary methods (see section on supplementary 
materials given at the end of this article).
Tissue microarrays, immunohistochemistry, and 
digital image analysis
Construction of tissue microarrays (TMAs) using 
formalin-fixed, paraffin-embedded (FFPE) tissues, 
immunohistochemistry of SDHA and SDHB, and digital 
image analysis are described in supplementary methods.
MALDI-MSI
Following tissue sample preparation (see supplementary 
methods), the MALDI-MSI measurement was performed 
on a Bruker Solarix 7T FT-ICR-MS (Bruker Daltonics, 
Bremen, Germany). The MALDI-MSI data were acquired 
over a mass range of m/z 50–1000. Mass imaging data were 
acquired in negative ionization mode with 70 μm spatial 
resolution using 50 laser shots at a frequency of 500 Hz. 
After the MALDI-MSI measurement, the acquired data 
from the tissue samples underwent spectra processing 
in FlexImaging v. 4.2 (Bruker Daltonics). Following the 
MALDI imaging experiments, the matrix was removed 
with 70% ethanol. The tissue sections were stained with 
H&E and scanned with a digital Mirax Desk slide scanner. 
Metabolite annotation was performed using METLIN, 
http://metlin.scripps.edu/ (22), the Human Metabolome 
Database (HMDB, http://www.hmdb.ca/) (23) and 
METASPACE, which is a framework for false discovery rate 
(FDR)-controlled metabolite annotation at the level of the 
molecular sum formula for high-mass-resolution imaging 
mass spectrometry (http://annotate.metaspace2020.
eu/) (24). Pathway enrichment analysis was applied to 
identify discriminative features of the mutation status 
of PPGLs, using Metabolite Set Enrichment Analysis 
with MetaboAnalyst 3.0 (http://www.metaboanalyst.ca) 
and the KEGG database (http://www.genome.jp/kegg/). 
Bioinformatics and statistical analysis are described in 
supplementary methods. Example images of distinct 
metabolites across a larger part of the TMA are provided 
in Supplementary Fig. 1. For assessment of potential 
confounding factors, 'sample age' was defined by the 
interval between TMA construction and time of surgery. 
Cell culture and siRNA transfection, quantitative real-
time PCR, immunoblotting and metabolome analysis of in 
vitro models are described in supplementary methods.
Results
Demographics
The clinical characteristics of the 331 included PPGL 
patients (153 men/178 women) with a median age at surgery 
of 50 (40–62) years) who had 344 tumors are summarized 
and stratified by the evidence of malignant behavior in Table 
1. For 188 patients, germline and somatic mutation status 
were available. Nineteen patients (with 21 tumor samples 
in total) were diagnosed with malignant PPGLs. Among 
those, larger tumor size, abdominal localization, low 
urinary metanephrine concentration and SDHB mutation 
were associated with the development of metastases (log-
rank tests P = 2.25E−04, 6.92E−05, 5.55E−06 and 6.97E−07, 
respectively, Supplementary Fig. 2A). Multivariable 
Cox proportional hazard modeling revealed that larger 
tumor size and SDHB mutation remained associated with 
malignant behavior (hazard ratio, 14.0 and 18.1; P = 0.032 
and 0.018, respectively), while stepwise regression 
rejected abdominal paraganglioma and lower urinary 
metanephrine concentration (Supplementary Table 1).
Immunohistochemistry and genotype/
phenotype correlation
Immunohistochemistry staining of SDHB and SDHA 
showed lower SDHB and higher SDHA staining intensity in 
SDHx mutated compared to SDHx wt tumors (P = 1.50E−13 
and 6.71E−06, respectively, Supplementary Fig. 2B and C). 
Staining intensity of SDHB (cut off <0.504) predicted the 
existence of SDHx mutation with an area under the curve 
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Evidence of malignancy  
PYes, n  = 19 No, n  = 306
Total, n 331 0.637
 Male, n 153 10 137
 Female, n 178 9 166
Age at surgery (years) 331 50 (40–62) 51 (46–64) 50 (40–62) 0.455
Maximal tumor size (mm) 309 45 (32–63) 73 (44–88) 45 (32–60) 0.007
Body mass index 220 24.8 (22.4–27.7) 24.6 (22.3–27.7) 24.9 (22.5–27.7) 0.952
SBP (mmHg) 186 137 (123–155) 137 (132–145) 136 (123–155) 0.833
DBP (mmHg) 186 82 (75–90) 82 (75–91) 80 (75–88) 0.671
Multifocal 320 0.705
 Yes 36 1 34
 No 284 17 267
Tumor location 338 <0.001
 PCC: adrenal 268 8 256
 PGL: head–neck 31 1 30
 PGL: thoracic 5 0 3
 PGL: abdominal 26 7 19
 PGL: pelvic 5 0 2
 Metastasis 3 – –
Biochemical data: 24 h urinalysis (μg/
day)
 Normetanephrine 178 2289 (775–5512) 1135 (275–3266) 2305 (805–5910) 0.062
 Metanephrine 189 617 (157–2770) 120 (81–157) 650 (195–2963) 0.001
 Methoxytyramine 65 258 (186–497) 216 (161–1048) 266 (190–492) 1.000
 Free norepinephrine 104 104 (49–297) 33 (27–211) 113 (58–300) 0.088
 Free epinephrine 105 17 (5–58) 4 (2–7) 20 (5–63) 0.005
 Free dopamine 120 247 (186–334) 241 (189–418) 254 (187–329) 0.956
Diabetes mellitus, n 102 1.000
 Yes 37 2 35
 No 65 5 60
Hypertension, n 267 0.316
 Yes 216 14 201
 No 51 1 50
Cardiovascular disease, n 107 0.255
 Yes 41 5 36
 No 66 3 63
Tumor mutation status, n 188 0.003
 Wildtype 43 1 42
 SDHA 2* 0 2
 SDHB 15 6 9
 SDHC 5† 0 5
 SDHD 12 1 11
 VHL 21 0 21
 EPAS1 4 0 4
 RET 36 0 36
 NF1 31 2 28
 TMEM127 2 0 2
 MAX 5 0 5
 HRAS 8 1 7
 VUS 4 0 4
P-values of less than 0.05 were considered significant and shown in bold. *One patient with SDHA and MDH2 mutation. †One patient with promoter 
methylation of SDHC gene.
DBP, diastolic blood pressure; PCC, pheochromocytoma; PGL, paraganglioma; SBP, systolic blood pressure; VUS, variant of unknown significance.
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of 0.928 and diagnostic sensitivity of 90.0% and specificity 
of 87.8% (Supplementary Fig. 2D). As expected, the low 
staining intensity of SDHB (cut off < 0.504) was associated 
with malignant behavior (log-rank tests P = 0.004, 
Supplementary Fig. 2E).
Metabolome profiles in correlation to genotypes
Unsupervised hierarchical clustering analysis of the 
MALDI-MSI dataset from 184 genetically annotated 
tumors revealed three groups with distinct metabolic 
pattern (Supplementary Fig. 3A); group a containing 19 
cluster 1 tumors (76.0%; SDHx, VHL and EPAS1 mutation), 
group b with 34 wt tumors (26.2%), and group c with 21 
cluster 2 tumors (72.4%; RET, NF1, TMEM127, MAX and 
HRAS mutation). An analysis of 144 tumors that belonged 
to cluster 1 and cluster 2 was performed by heat map 
based cluster analysis and ortho-PLSDA (Fig. 1A and B). 
Thereby, three groups were identified with group A, in 
which 23 tumors (74.2%) were from cluster 1, group B, in 
which an equal number of cluster 1 and 2 tumors were 
included, and group C, in which 45 tumors from cluster 
2 (86.5%) were included (Fig. 1A). While overlap and 
continuous changes were evident between cluster 1 and 
2 PPGLs, among approximately 2000 m/z species over a 
mass range of 50–1000 m/z, 266 metabolites were found 
to be significantly different (more than two-fold change 
and P < 0.05) between the two clusters. Expectedly, these 
included metabolites related to catecholamine synthesis, 
such as L-DOPA and 3-methoxytyramine sulfate, which 
were more abundant in cluster 2 (P = 6.42E−06 and 
1.40E−05, respectively, Fig. 1C) and norepinephrine with 
higher abundance in cluster 1 (P = 0.023, Fig. 1C).
To take into account a potential bias based on 
sample age, differences in sample fixation and specimen 
preparation, we assigned age and center of individual 
samples to PLSDA. Notably, and at variance to the 
genetic status, neither sample age nor place of origin did 
significantly impact on the attribution of the individual 
sample data to the cluster1 or 2 (Supplementary Fig. 3B).
Pathway enrichment analysis of significantly different 
metabolites between cluster 1 and 2 revealed altered 
pathways such as 'purine metabolism', 'tryptophan 
metabolism', 'pyruvate metabolism', 'inositol metabolism', 
among others (Supplementary Table 2A). Metabolites 
related to purine metabolism, AMP, ADP and ATP, were 
found to be more abundant in cluster 2 (P = 2.64E−04, 
0.022 and 0.002, respectively, Fig. 1D). Further cluster-
restricted examination revealed additional differences 
in purine metabolism with a higher adenine nucleoside 
phosphate content in VHL mutated tumors in comparison 
to SDHx mutated tumors (Supplementary Fig. 3C). In 
addition, metabolites related to tryptophan metabolism, 
including xanthurenic acid and 8-methoxykynurenate, 
were found to be significantly more abundant in cluster 
2 tumors (P = 2.35E−09 and 5.06E−11, respectively, Fig. 
1E and Supplementary Table 2A). As both metabolites are 
part of the kynurenine pathway, further members of this 
pathway were analyzed more closely and kynurenic acid 
and 7,8-dihydroxykynurenic acid were more abundant 
in cluster 2, although with a less than two-fold difference 
(fold change = 1.948 and 1.890, P = 3.07E−06 and 1.01E−05, 
respectively).
Comparison of metabolic profiles between tumor 
and in vitro samples
In order to provide further insights into the pathogenic 
mechanisms of PPGLs, we compared the metabolic profiles 
between in situ samples and in vitro cell models. siRNA 
knockdown of Sdhb and Vhl genes was introduced in PC12 
cells (Supplementary Fig. 4A and B). Thereby, we found 
that knockdown of Sdhb expression in PC12 cells led to the 
accumulation of succinate and a higher succinate/fumarate 
ratio (Supplementary Fig. 4C) as expected for cluster 1 
tumors. Considering the fact that PC12 cells are lacking 
a functional Max gene (25, 26), cells transfected with 
scrambled siRNA were expected to represent a cluster 2-like 
status. Using these in vitro models, 198 and 227 metabolites 
were identified as differentially regulated (P < 0.05) in 
Sdhb and Vhl knockdown cells in comparison to cells 
transfected with scrambled siRNA, respectively. Thirty-
two metabolites such as tryptophan (P = 0.001 and 0.014, 
respectively, Supplementary Fig. 4D) were commonly 
more abundant in Sdhb and Vhl knockdown cells. Seventy-
five metabolites were commonly decreased in Sdhb and 
Vhl knockdown cells. Based on pathway enrichment 
analysis, these were classified into 'purine metabolism', 
'amino sugar metabolism' and 'fatty acid biosynthesis' 
(Supplementary Table 2B). As pathway enrichment 
analysis indicated, metabolites of 'purine' and 'pyrimidine 
metabolism' in human PPGLs to be decreased in cluster 
1 (Supplementary Table 2A and Fig. 2A), we focused on 
nucleoside-related metabolites in the PC12 cell models. 
In Sdhb and Vhl knockdown cells we observed decreased 
amounts of inosine (both P = 0.006 vs scrambled siRNA, 
Fig. 2A and B) and uridine (both P = 0.002, Fig. 2A and B). 
Compounds related to inositol metabolism were decreased 
in cluster 1 (Supplementary Table 2A and Fig. 2A), and 
accordingly, inositol cyclic phosphate as inositol-related 
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Figure 1
Tissue metabolomic profiles of PPGLs. Unsupervised hierarchical clustering analysis (A) and orthogonal partial least squares 
discriminant analysis (Ortho-PLSDA, B) of metabolome profiles of 141 PPGLs separates cluster 1 and 2. Groups based on 
metabolite pattern, mutation status, tumor location and metastatic behavior are shown below the heat map. Distribution of 
patient numbers with regard to mutation status is shown. Intensities of the catecholamine metabolites L-dopa, 
3-methoxytyramine sulfate, and norepinephrine, in clusters 1 and 2 and representative images are shown in (C). Significant 
differences of purine metabolites AMP, ADP and ATP are depicted in (D), and of tryptophan metabolites xanthurenic acid and 
8-methoxykynurenate in (E). Mann–Whitney U test and Kruskal–Wallis test were used for statistical analysis. *P < 0.05, **P < 
0.001. Scale bars: 500 μm.
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Figure 2
Comparison of metabolomic features between PPGLs and PC12 cells. Comparison of metabolites included in 'metabolites 
containing nucleoside', 'inositol metabolism' and 'amino sugar and its derivatives' with regard to 'cluster 1 vs cluster 2' in human 
PPGLs and 'siSdhb or siVhl vs scrambled siRNA' in PC12 cells (A). Significant differences inosine, uridine, inositol cyclic phosphate, 
N-acetylneuraminic acid, glucosamine, and lactosamine in PC12 cells were observed (B). Mann–Whitney U test and Kruskal–Wallis 
test were used for statistical analysis. *P < 0.05.
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metabolite was also decreased in Sdhb and Vhl knockdown 
PC12 cells (P = 0.003 and 0.002, Fig. 2A and B). Decreased 
abundance of N-acetylglucosamine 6-sulfate and sialic 
acids such as N-glycolylneuraminic acid and N-acetyl-9-O-
lactoylneuraminic acid were observed in cluster 1 human 
tumors (P = 1.53E−09, 0.002 and 1.65E−05, respectively, 
Fig. 2A). In Sdhb and Vhl knockdown cells we found less 
aminosugars N-acetylneuraminic acid (P = 0.001 and 
4.19E−04, respectively), glucosamine (P = 0.012 and 
0.002, respectively), and lactosamine (P = 2.69E−04 and 
5.06E−05, respectively, Fig. 2A and B).
Impact of metabolic profiles on the diagnosis of 
metastatic PPGLs
Tissue metabolomic parameters were further correlated 
with clinical annotation of malignancy. Because clinical 
exclusion of malignant PPGL is dependent on an 
appropriate follow-up period, non-metastatic PPGL was 
defined as the absence of metastasis after a follow-up of 
more than 5 years. Based on this cohort of 35 patients 
(Supplementary Table 3), clustering analysis revealed 
distinct metabolite profiles between malignant and 
apparently benign PPGLs (Fig. 3A), with 154 metabolites 
being significantly different (with a more than two-fold 
change and P < 0.05) between the groups. We further 
assessed occurrence of metastasis with the Kaplan–Meier 
method and log-rank test using optimized cutoffs for 
metabolite intensity. Forty-eight metabolites (of which 18 
could be annotated) in primary tumors were significantly 
associated with metastasis-free survival (Table 2). 
Metabolites implicated in the kynurenine pathway such 
as xanthurenic acid (Fig. 3B), 7,8-dihydroxykynurenic 
acid, kynurenic acid and 8-methoxykynurenate were 
among the metabolites with a predictive value (log-rank 
tests P = 7.96E−06, 2.09E−04, 2.35E−04, and 2.83E−04, 
respectively, Table 2). The number of kynurenine 
pathway metabolites with lower than cut-off intensity 
was associated with shorter metastasis-free survival (log-
rank tests P = 1.66E−05, hazard ratio, 3.61, P = 2.33E−04, 
Fig. 3C). Thereby, PPGLs enriched in metabolites of the 
kynurenine pathway were found to be associated with a 
more favorable biological behavior. Multivariate analysis, 
including the intensity of metabolite, maximal tumor 
size (>74 mm vs ≤74 mm) and SDHB mutation status 
(mutated vs wild type), revealed nine metabolites as 
independent factors for metastasis-free survival (Table 2). 
By using SDHB staining intensity (<0.504 vs ≥0.504) in 
lieu of mutation status, multivariate analysis including the 
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13 metabolites as independent factors for metastasis-free 
survival. Seven metabolites, including xanthurenic acid 
and 7,8-dihydroxykynurenic acid from the kynurenine 
pathway, were overlapping for both SDHB mutation status 
and SDHB staining intensity. In addition, low xanthurenic 
acid levels predicted the existence of metastasis 
(AUC = 0.809, 95% CI = 0.654–0.964, P = 9.59E−05) with 
higher accuracy than SDHB mutation status (AUC = 0.772, 
95% CI = 0.611–0.933, P = 9.44E−04) and maximum 
tumor size (AUC = 0.599, 95% CI = 0.366–0.831, P = 0.405, 
Fig. 3D) alone. To combine the intensity of metabolites, 
maximal tumor size and SDHB mutation status or – as an 
alternative – SDHB staining intensity, a scoring system was 
established to assess the risk of metastasis. Using the low 
intensity of xanthurenic acid (<0.378), larger tumor size 
(>74 mm), SDHB mutation (mutated), the sum of these risk 
factors could discriminate metastatic from non-metastatic 
PPGLs (hazard ratio, 5.427; P = 3.46E−05, Fig. 3E). From 
60 patients, eight were diagnosed with metastatic disease. 
Seven of those (88%) had low xanthurenic acid tissue 
intensity. On the other hand, only five patients (63%) 
developed metastasis in the context of SDHB mutation. 
Thus, two additional patients with metastasis could be 
identified by using low xanthurenic acid tissue intensity 
as a marker of malignant behavior (Supplementary Fig. 
5A). When applying lower SDHB staining intensity 
(<0.504) instead of SDHB mutation status (mutated) as a 
risk factor, the scoring system remained discriminative for 
PPGLs with metastasis (hazard ratio, 4.818; P = 1.30E−06, 
Supplementary Fig. 5B). Overall, a low abundance of 
metabolites in the tryptophan and kynurenine pathways 
were found to be associated with metastatic disease and in 
the context of cluster 1 mutations (Fig. 3F).
Discussion
Herein, we report an in-depth analysis of tissue metabolome 
profiles based on MALDI-mass spectrometry imaging 
in a large cohort of PPGL patients. Based on the current 
untargeted metabolomic profiles, we provide insight in 
the specific metabolic alterations related to the genetic 
events present in cluster 1 and cluster 2 tumors. We still 
found a group of tumors with an intermediate metabolic 
phenotype of more gradual changes in some metabolites 
leading to overlap between the genetic clusters.
A previous study had demonstrated a higher succinate/
fumarate ratio, a well-known hallmark of SDHx mutated 
tumors, in FFPE samples, by applying ultrahigh-pressure 
liquid chromatography with tandem mass spectrometry 
(15). Based on the current untargeted metabolomic 
profiles, we further found contrasting patterns between 
tumors of cluster 1 and cluster 2, although gradual changes 
of some metabolites with overlap between the clusters were 
present as well. Metabolites related to 'purine metabolism' 
including AMP, ADP and ATP were present at lower 
levels in cluster 1 tumors, consistent with findings from 
previous studies using proton NMR (16, 17). Disruption of 
respiratory enzyme complex II in SDHx mutated tumors is 
likely to reduce tumor content of AMP/ADP/ATP. Previous 
studies have indicated increased glycolysis preferentially 
in VHL mutated tumors (27) and higher accumulation of 
AMP/ADP/ATP in VHL in comparison to SDHx mutated 
tumors (28, 29). Our observation based on MALDI imaging 
corroborates these reports in terms of ADP distribution in 
SDHx and VHL mutated tumors. 
It has been shown that lower tissue catecholamine 
content is a characteristic of tumors from cluster 1 (30). 
Our observation confirmed lower contents of L-dopa and 
3-methoxytyramine sulfate as catecholamine-related 
metabolites in cluster 1. The presence of the sulfated 
metabolite of dopamine in cluster 2 was unexpected 
because it had not been reported previously. In fact, all 
previous analyses of tumor metabolites were targeted 
approaches, for example, focusing on Krebs cycle 
metabolites or polyamines. Canonically, sulfation of 
3-methoxytyramin is considered to occur mostly in the 
liver. However, interrogation of TCGA data demonstrated 
that a variety of sulfotransferases is expressed at different 
levels in PPGL (data not shown) and might contribute 
to the sulfation of 3-methoxytyramine. Although the 
previous study had demonstrated, that cluster 2 tumors 
contained more norepinephrine and epinephrine than 
those of cluster 1, the higher amounts of norepinephrine 
in cluster 1 tumors observed in the present study could 
well be related to a lack of PNMT gene expression, which is 
a representative feature of cluster 1 PPGLs (30). While it is 
possible that the stability of catecholamines in FFPE tissue 
might have affected the measurement of norepinephrine, 
generally, the tissue metabolome profiles did not depend 
on sample age and center distribution (Supplementary Fig. 
3B).
We further used PC12 cells, which lack a functional 
Max gene that results in a cluster 2-like status. By 
knockdown of Sdhb and Vhl, we implemented a model of 
cluster 1-like status. Lower contents of N-acetylneuraminic 
acid in PC12 cells and N-acetyl-9-O-lactoylneuraminic 
acid and N-glycolylneuraminic acid in human PPGLs were 
evident in cluster 1 (-like status). There is a growing body of 
evidence demonstrating that cancer cells have significantly 
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Figure 3
Tissue metabolome characteristics of metastatic PPGLs. Unsupervised hierarchical clustering analysis of metabolome profiles of 
36 metastatic and non-metastatic PPGLs with long term follow-up are provided in (A). Kaplan–Meier plots for metastasis-free 
survival in relation to high and low xanthurenic acid (B). Kaplan–Meier plots for metastasis-free survival based on the number of 
metabolites with low intensity in kynurenine pathway xanthurenic acid (<0.378), 7,8-dihydroxykynurenic acid (<0.674), kynurenic 
acid (<1.110) and 8-methoxykynurenate (<0.276) (C). ROC curves for prediction of metastatic behavior by xanthurenic acid, SDHB 
mutation status and maximal tumor size and area under curves (AUC) are provided (D). Kaplan–Meier plots for metastasis-free 
survival in relation to a scoring system using maximal tumor size, SDHB mutation status and xanthurenic acid (E). Kaplan–Meier 
plots for metastasis-free survival in relation to the scoring system and the examination of the scoring system by cox proportional 
hazards model are shown. Log-rank test was used to statistically compare the curves and P-values are provided. Schematic 
diagram of tryptophan metabolism (F). Metabolites with low intensity in cluster 1 in comparison to cluster 2 are indicated as red 
arrows. Metabolites with low intensity and associated with metastatic PPGLs are indicated as blue arrows.
Downloaded from Bioscientifica.com at 08/31/2021 07:27:08AM
















185:1 189Clinical Study M Murakami, N Sun and 
others
In situ metabolomics of PPGLs
https://eje.bioscientifica.com
elevated levels of sialic acid (31). Although detailed 
mechanisms between the genotype and the content of 
sialic acids in PC12 cells and PPGLs are to be elucidated, it is 
interesting to note this is a common molecular fingerprint 
of cluster 1 (-like status) in human PPGLs and PC12 cells 
that underscores its potential functional relevance.
 Discrimination of metabolome profiles with 
respect to malignant and apparently benign PPGLs 
identified 18 metabolites, which were associated with 
metastasis-free survival. Nine of these metabolites 
were significantly associated with malignant potential 
independently of clinical features and SDHB mutation 
status. Thereby, our findings add to molecular markers that 
earlier studies had identified, such as telomerase activation, 
ATRX gene mutations and specific miRNA signatures to 
predict the existence of metastatic PPGLs (32, 33).
The significant correlation between metastatic spread 
and kynurenine pathway metabolites sheds light on 
potential disease mechanisms. We observed low intensity 
of tryptophan-related metabolites in cluster 1 tumors, 
while metabolites related to serotonin such as 5-HIAA 
and 5-methoxyindoleacetate were not associated with 
metastatic behavior. Conversely, metabolites from the 
kynurenine pathway were less abundant in cluster 1 
tumors and further associated with metastatic behavior. 
The kynurenine pathway is the principal route of 
tryptophan catabolism. Overproduction of kynurenine 
from tryptophan, which is an initial step of the kynurenine 
pathway and promoted by overactivation of indoleamine 
2,3-dioxygenase (IDO), is known to predict poor prognosis 
of several cancers (34). While kynurenine was not among 
the differentially distributed metabolites between benign 
and malignant PPGLs in our analysis, kynurenic acid 
and xanthurenic acid were detected at lower intensities 
in malignant PPGLs. It is conceivable that – beyond 
the immunological role of the kynurenine pathway – 
kynurenic acid itself may have anti-proliferative activity 
similar to what has been reported for colon cancer and 
renal cancer cell lines (35, 36).
There are some limitations of the current study that 
need to be considered: distribution of metabolites in FFPE 
tissues, which were used for the MALDI imaging analysis, 
are likely affected by fixation and embedding procedures. 
Despite this potential bias, our observation of decreased 
nucleoside phosphates in cluster 1 tumors is consistent 
with previous studies and confirms the validity of our 
analysis. In addition, we recover catecholamines and 
their metabolites as positive controls. While we identified 
metabolic pathways associated with the malignant 
potential of PPGLs, metastasis-free survival rate, could 
only be calculated for 109 from 344 tumors because 
of the required long follow-up. Similarly, multivariate 
analysis, which required tumor size, mutation status and 
metabolite data, was restricted to only 60 tumors because 
of missing data mainly on the tumor mutation status. 
In addition, as PPGLs can recur or metastasize very late 
in the course of the disease any restricted observation 
period includes limitations in the grouping of apparently 
benign tumors. The applied observation period of five 
years represents a compromise that balances a clinically 
meaningful time frame with the availability and age of 
samples and the resulting group size. Finally, considering 
the exploratory character of our study, confirmatory tests 
should be performed in the future. While it will be difficult 
to implement a similarly large study using FFPE tissues, 
more focused metabolomic approaches on prospectively 
collected fresh frozen tissue and in experimental model 
systems would be useful to validate and extend our 
findings.
In summary, the present study indicates distinct 
metabolomic profiles of PPGLs with regard to genotype 
classification between clusters 1 and 2. Comparison of 
metabolome between PPGLs and in vitro model showed 
similarities in inositol metabolism and the differential 
expression of sialic acid between clusters 1 and 2. The 
association of low kynurenine pathway activity in 
metastatic PPGL is novel and provides unprecedented 
insights into the pathophysiology of PPGLs.
Supplementary materials
This is linked to the online version of the paper at https://doi.org/10.1530/
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